MIRA expands Ketamir-2 license from North America to global patent territories

Filed May 27, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  MIRA expanded exclusive rights to develop Ketamir-2 from US, Canada, and Mexico to all countries where patent rights exist, significantly broadening potential market opportunity for the Phase 2a drug candidate.

  Item 1.01 verify on EDGAR →
• high

  Licensed patent portfolio now covers ten major markets including US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea, strengthening competitive position and IP protection globally.

  Item 1.01 verify on EDGAR →
• medium

  Amendment did not change core economic terms including royalty obligations and financial consideration, meaning MIRA secured expanded global rights without renegotiating payment terms or disclosed additional costs.

  Item 1.01 verify on EDGAR →